Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Not applicable Interventional

Evaluation of Amniotic Fluid Product in Knee Osteoarthritis

NCT02768155
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
30 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction

NCT01220726
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

NCT02289716
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Placebo, Ocrelizumab, Avonex
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

NCT01725126
View directory record Official record
Conditions
Obesity
Interventions
GSK2890457, Metformin, Placebo, Liraglutide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 17, 2026, 4:02 PM EDT
Terminated Phase 3 Interventional Results available

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT05398263
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Newport Beach, California • Denver, Colorado • Newark, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

NCT03593785
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
AZD8233
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 17, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258464
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

NCT02379052
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 17, 2026, 4:02 PM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers

NCT01542632
View directory record Official record
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 3 Interventional

A Study of SI-6603 in Patients With Lumbar Disc Herniation

NCT01941563
View directory record Official record
Conditions
Intervertebral Disc Disease, Lumbar Disc Disease
Interventions
Condoliase, placebo
Drug
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
30 Years to 70 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Gold River, California • Laguna Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

NCT02766621
View directory record Official record
Conditions
Healthy
Interventions
PF-06823859, Placebo injection SC/IV
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Not applicable Interventional

Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee Osteoarthritis

NCT03074526
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Amniotic Fluid, Saline Placebo
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Des Plaines, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 17, 2026, 4:02 PM EDT
Recruiting Phase 3 Interventional

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

NCT07622108
View directory record Official record
Conditions
Thyroid Eye Disease, TED
Interventions
MHB018A, MHB018A placebo
Drug
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin Effects on Plantar Ulcer Recurrence

NCT00845897
View directory record Official record
Conditions
Diabetes Mellitus, Peripheral Neuropathy, Plantar Ulcers
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 17, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

NCT06665646
View directory record Official record
Conditions
HIV Infections
Interventions
CD40.HIVRI.Env (VRIPRO), Hiltonol Poly-ICLC-adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496
View directory record Official record
Conditions
Endocrine Tumors
Interventions
lanreotide (Autogel formulation), Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 2 Interventional

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

NCT06015308
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Tdap vaccine, PPS vaccine
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 4:02 PM EDT